Investigational compound
CJC-1295 + Ipamorelin: Component Evidence vs Blend Evidence
CJC-1295 + Ipamorelin — component evidence vs blend evidence
Overview
CJC-1295 and Ipamorelin act on different parts of the growth-hormone-release axis, but that does not mean the commercial combination has clinical evidence of its own. The available human studies mainly evaluate each compound separately, or combinations of other molecules in the same classes.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone / growth hormone-releasing factor. Ipamorelin is a synthetic pentapeptide growth hormone secretagogue acting through the growth-hormone-secretagogue / ghrelin receptor system. Different receptor pathways do not establish that the exact pair is synergistic, effective, safe, or superior.1,5,12
Two molecules, two pathways
Evidence belongs toCJC-1295
CJC-1295
A synthetic GHRH / growth hormone-releasing factor analogue. The principal human literature used a long-acting form with a drug-affinity complex (DAC).1,15
Evidence belongs toIpamorelin
Ipamorelin
A synthetic pentapeptide growth hormone secretagogue acting through the ghrelin / GHS receptor.5,6
Receptor detail is in GHRH, ghrelin, and two signaling pathways. Mechanism explains why the two names are discussed together. It does not replace a trial of the blend.
Before discussing the blend: which CJC was studied
FDA evaluated several related bulk substances separately: CJC-1295 free base, acetate, DAC free base, DAC acetate, and DAC trifluoroacetate. They are not chemically identical, and pharmacokinetic data should not be silently transferred among them.15,16
Catalogs and online copy often use phrases such as “CJC-1295 without DAC,” “CJC-1295 no DAC,” “modified GRF (1-29),” or “Mod GRF 1-29.” Those labels are not perfectly standardized synonyms. FDA documented identity and naming inconsistencies in the nominations.15,12
Peptra’s current catalog identifies the vial’s CJC component as CJC-1295 (No DAC), a modified GRF(1-29) analog, 10 mg together with 10 mg of ipamorelin. That is a product-identity claim, not a confirmation that the lot matches the DAC material used in the 2006 trials. The detail is in CJC-1295 with DAC vs no DAC.
Evidence map
Editorial map reviewed as of September 1, 2026. This is not a meta-analysis.
| Evidence | CJC-1295 | Ipamorelin | Exact combination |
|---|---|---|---|
| Human pharmacology | Yes, DAC form | Yes, PK/PD | None identified |
| Randomized human outcome trial | Pharmacology / biomarkers | Phase 2 ileus: key endpoint not significant | None identified |
| Phase 2 registry | NCT00267527, Terminated | Two completed records | None identified |
| Demonstrated clinical efficacy | Not for a disease-treatment use | Not on the published GI endpoint | None identified |
| Long-term safety | Limited data | Limited data | None identified |
| Regulatory approval | Not an FDA-approved drug | Not an FDA-approved drug | No |
Direct blend evidence
Evidence belongs toExact combination
In the sources reviewed as of September 1, 2026, we did not identify a human interventional trial that administered CJC-1295 and Ipamorelin together. We also did not identify a ClinicalTrials.gov trial of the exact pair.1,7,4,9
A 2026 orthopaedic review mentions CJC-1295 combined with ipamorelin in a murine context. The primary citations for that passage administered ipamorelin alone in rats. That secondary claim is not treated here as exact-pair evidence.13,14
The inventory is in whether there is human evidence for the combination.
Why a combination hypothesis exists
Evidence belongs toRelated pathway / other compounds
There is older human literature in which a GH-releasing peptide acts together with GHRH, and literature in which ghrelin interacts with GHRH. Those molecules are not Ipamorelin or CJC-1295.10,11
That supplies a class-level mechanistic analogy: two distinct pathways can interact on GH secretion. It does not supply clinical evidence for the commercial pair. Mechanism is developed in the two signaling pathways.
What the individual studies do show
Teichman and colleagues, 2006, measured sustained GH and IGF-I increases after long-acting CJC-1295 in healthy adults. Ionescu and Frohman showed that GH pulsatility persisted. Sackmann-Sala analyzed protein profiles in samples from an existing cohort.1,2,3
Gobburu and colleagues modeled ipamorelin pharmacokinetics and GH response in volunteers. Beck and colleagues published a Phase 2 postoperative-ileus trial that did not find a statistically significant difference on the key efficacy endpoint.6,7
Those findings are detailed in CJC-1295 in humans and Ipamorelin in humans.
What cannot be added together
- CJC-1295-alone evidence plus Ipamorelin-alone evidence is not combination evidence.1,6
- A GH or IGF-I increase is not muscle gain, fat loss, recovery, anti-aging, sleep, or performance.1,2
- DAC pharmacology is not automatically assigned to a no-DAC material.1,12
- Synergy of GHRH with other GHRPs or with ghrelin is not demonstrated synergy of CJC-1295 + Ipamorelin.10,11
- A blend certificate of analysis documents vial identity and purity. It does not demonstrate pharmacodynamic interaction or clinical efficacy.
FDA 2024 and current status
Neither CJC-1295 nor Ipamorelin is an FDA-approved drug. PCAC reviewed Ipamorelin forms on October 29, 2024 and five CJC-1295-related forms on December 4, 2024. In both cases FDA proposed against inclusion on the 503A Bulks List. The votes were advisory recommendations, not a drug approval or ban.16,18,22
As of September 1, 2026, we did not identify a later final rule placing them on the 503A list. CJC-1295 appears on the official withdrawn-nomination table. Ipamorelin acetate remains Category 2 under the 503B interim policy and is also listed among withdrawn nominations. Detail is in FDA, compounding, and WADA status.21,19,20
WADA 2026
WADA’s 2026 Prohibited List, section S2.2.4, explicitly names CJC-1295 as a GHRH analogue and ipamorelin as a growth hormone secretagogue / mimetic. That is informational context, not detection or evasion guidance.23,24
What we do not know
- What would happen in a human trial that administered the two specific molecules from a commercial vial together.13
- Whether a no-DAC material reproduces the exposure of the DAC form published in 2006.1,12
- Long-term safety of either compound outside the short clinical programs already published.15,21
- Why NCT00267527 is Terminated; the registry record alone does not establish the cause.4
- Efficacy numbers for NCT01280344: the registry is Completed and, as of the September 2026 review, posts no results.9
Explore research
Six pages cover distinct intents: DAC versus no-DAC identity; human CJC-1295 evidence; human Ipamorelin evidence; the two receptor pathways; exact-pair evidence; and FDA/WADA status.
Analytical documentation
A blend COA can report analytical identity and purity of the material. It does not prove pharmacodynamic synergy, clinical safety, or clinical efficacy. See the CJC-1295 / Ipamorelin certificate archive and, if you are looking for the research material, the product page.
Explore the cluster
- CJC-1295 With DAC vs No DAC: Why Identity Matters
The long-acting human pharmacology was obtained with a form designed to bind albumin. That exposure is not automatically assigned to a no-DAC material.
- CJC-1295 in Humans: What Clinical Studies Exist
Human pharmacology of a DAC form exists in healthy adults. That is not a completed disease-treatment trial and not evidence for the Ipamorelin blend.
- Ipamorelin in Humans: Pharmacology, Phase 2 & Evidence Limits
Human pharmacology exists, and a Phase 2 ileus trial missed its key endpoint. That is not blend evidence and not a proof of GH-axis efficacy.
- CJC-1295 & Ipamorelin: GHRH, Ghrelin & Two Signaling Pathways
Two signaling pathways on the somatotroph are not a trial of the exact pair. A mechanistic analogy is not demonstrated synergy of CJC-1295 + Ipamorelin.
- CJC-1295 + Ipamorelin: Is There Human Evidence for the Combination?
In the sources reviewed as of September 1, 2026, we did not identify a human trial of the exact pair. Adding the components together does not create blend evidence.
- CJC-1295 & Ipamorelin: FDA, Compounding & WADA Status
Information reviewed as of 1 September 2026. An advisory compounding vote is not drug approval and is not Mexican law.
Related documentation
References
Peer-reviewed clinical trial
Studied moleculeCJC-1295 DAC
Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA.
Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.J Clin Endocrinol Metab. 2006;91(3):799-805. 2006
Two randomized, placebo-controlled, double-blind ascending-dose studies in healthy adults aged 21–61 years. Endpoints were GH, IGF-I, and pharmacokinetics of a long-acting DAC form. Not a body-composition, performance, or combination trial.
Peer-reviewed primary research
Studied moleculeCJC-1295 DAC
Ionescu M, Frohman LA.
Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog.J Clin Endocrinol Metab. 2006;91(12):4792-4797. 2006
Human endocrine-physiology study in healthy men after CJC-1295. It addresses GH pulsatility, not body composition and not the CJC-1295 + Ipamorelin blend.
Peer-reviewed primary research
Studied moleculeCJC-1295 DAC
Sackmann-Sala L, et al.
Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects.Growth Horm IGF Res. 2009;19(6):471-477. 2009
DOI 10.1016/j.ghir.2009.03.001
Proteomic / biomarker analysis of samples from an existing CJC-1295 cohort. Not counted as an independent efficacy trial.
Clinical trial registry
Studied moleculeCJC-1295 DAC
A Study to Evaluate CJC 1295 in HIV Patients With Visceral ObesityClinicalTrials.gov NCT00267527. 2006
NCT00267527 · Registry status as reviewed: Terminated · checked September 1, 2026
Reported sample size: 120
No results posted
Phase 2 randomized, placebo-controlled, double-blind registry record. Planned enrollment 120. Status Terminated. Registry status alone does not establish why the study stopped.
Preclinical study — animal
Studied moleculeIpamorelin
Raun K, Hansen BS, Johansen NL, et al.
Ipamorelin, the first selective growth hormone secretagogue.Eur J Endocrinol. 1998;139(5):552-561. 1998
Preclinical pharmacology in rat pituitary cells, rats, and swine. Selectivity findings from this paper are not unconditional human safety language.
Peer-reviewed primary research
Studied moleculeIpamorelin
Gobburu JVS, Agersø H, Jusko WJ, Ynddal L.
Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers.Pharm Res. 1999;16(9):1412-1416. 1999
Reported sample size: 40
Human PK/PD study in healthy male volunteers at five infusion-rate levels with eight subjects at each level. Establishes pharmacology, not fat-loss, muscle, sleep, performance, or blend efficacy.
Peer-reviewed clinical trial
Studied moleculeIpamorelin
Beck DE, Sweeney WB, McCarter MD; Ipamorelin 201 Study Group.
Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients.Int J Colorectal Dis. 2014;29(12):1527-1534. 2014
NCT00672074
Reported sample size: 117
Phase 2 randomized trial. Enrollment 117; safety / modified ITT 114. The key efficacy endpoint, time to tolerance of a standardized solid meal, did not reach statistical significance. Not blend evidence.
Clinical trial registry
Studied moleculeIpamorelin
Safety and Efficacy of Ipamorelin for Management of Post-Operative IleusClinicalTrials.gov NCT00672074. 2009
NCT00672074 · Registry status as reviewed: Completed · checked September 1, 2026
Reported sample size: 117
Published as Beck 2014
Phase 2 registry companion to the published Beck 2014 paper. Registry completion is not independent efficacy evidence beyond the published report.
Clinical trial registry
Studied moleculeIpamorelin
Safety and Efficacy of Ipamorelin Compared to Placebo for the Recovery of Gastrointestinal FunctionClinicalTrials.gov NCT01280344. 2014
NCT01280344 · Registry status as reviewed: Completed · checked September 1, 2026
Reported sample size: 320
No results posted
Completed Phase 2 registry record, enrollment 320, study completion May 2014. No results posted on ClinicalTrials.gov as of the 1 September 2026 review. A completed registry is not a published numerical efficacy paper.
Peer-reviewed primary research
Studied moleculeOther GHRH + GHS pair
Bowers CY, et al.
Growth hormone (GH)-releasing peptide stimulates GH release in normal men and acts synergistically with GH-releasing hormone.J Clin Endocrinol Metab. 1990. 1990
Human mechanistic combination study of a GH-releasing peptide with GHRH. Not a study of Ipamorelin plus CJC-1295.
Peer-reviewed primary research
Studied moleculeGhrelin + GHRH
Arvat E, et al.
Endocrine activities of ghrelin, a natural growth hormone secretagogue (GHS), in humans: comparison and interactions with hexarelin, a nonnatural peptidyl GHS, and GH-releasing hormone.J Clin Endocrinol Metab. 2001. 2001
Human endocrine/mechanistic study of ghrelin, hexarelin, and GHRH. Not a study of Ipamorelin plus CJC-1295.
Scientific review
Studied moleculeCJC-1295, form not specified
Dominikowski A, et al.
The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration.Front Endocrinol. 2026. 2026
DOI 10.3389/fendo.2026.1822475
Scientific review of unapproved GH-axis peptides, including the DAC versus non-DAC distinction and the gap between clinical research and self-administration. A review does not replace primary sources.
Scientific review
Studied moleculeExact CJC-1295 + Ipamorelin pair
Mayfield CK, et al.
Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians.Am J Sports Med. 2026. 2026
Narrative sports-medicine review. The results text attributes a murine tetanic-tension finding to CJC-1295 combined with ipamorelin, but the cited primary experiments administered ipamorelin alone. Cited here as a secondary claim to be audited, not as exact-pair evidence.
Preclinical study — animal
Studied moleculeIpamorelin
Andersen NB, Malmlöf K, Johansen PB, Andreassen TT, Ørtoft G, Oxlund H.
The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation of adult rats.Growth Horm IGF Res. 2001;11(5):266-272. 2001
Adult-rat study of ipamorelin alone under glucocorticoid exposure. Not a CJC-1295 + Ipamorelin combination experiment and not a human trial.
Regulatory source
Studied moleculeCJC-1295, form not specified
December 4, 2024 Pharmacy Compounding Advisory Committee — FDA Briefing Document for CJC-1295 Related Bulk Drug SubstancesFDA PCAC briefing. 2024
Regulatory source — United States
FDA staff evaluation of five CJC-1295-related bulk substances for a nominated growth-hormone-deficiency use. Human studies were primarily in healthy subjects. Not a final rule and not drug approval.
Regulatory source
Studied moleculeCJC-1295, form not specified
Final Summary Minutes of the Pharmacy Compounding Advisory Committee Meeting, December 4, 2024FDA PCAC minutes. 2024
Regulatory source — United States
Official advisory-committee votes. FDA proposed against inclusion on the 503A Bulks List. These votes are not drug-approval decisions and are not a published final rule.
Regulatory source
Studied moleculeIpamorelin
October 29, 2024 Pharmacy Compounding Advisory Committee — FDA Briefing Document for Ipamorelin-Related Bulk Drug SubstancesFDA PCAC briefing. 2024
Regulatory source — United States
FDA staff evaluation of ipamorelin free base and ipamorelin acetate for growth hormone deficiency and postoperative ileus. Not a final rule and not drug approval.
Regulatory source
Studied moleculeIpamorelin
Final Summary Minutes of the Pharmacy Compounding Advisory Committee Meeting, October 29, 2024FDA PCAC minutes. 2024
Regulatory source — United States
Official advisory-committee votes on ipamorelin free base and acetate. FDA proposed against inclusion on the 503A Bulks List. Advisory recommendation, not drug approval.
Regulatory source
Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C ActFDA 503A compounding page. 2026
Regulatory source — United States
Official description of the 503A bulks list, the 2019 final rule, later proposed amendments, and interim Category 1/2/3 policy. Category placement is not drug approval.
Regulatory source
Bulk Drug Substances Nominated for Use in Compounding Under Section 503AFDA 503A nominated-substance list. 2026
Regulatory source — United States
Official 503A nomination categories reviewed as of the September 1, 2026 evidence date. Absence from Category 1 or the final bulks list is not itself a published final exclusion rule for every named peptide. Same FDA document as the GHK-Cu nomination entry; kept as a distinct ID because CJC/Ipamorelin pages cite this context.
Regulatory source
Studied moleculeCJC-1295, form not specified
Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety RisksFDA compounding safety page. 2026
Regulatory source — United States
As reviewed on 1 September 2026: CJC-1295 appears on the withdrawn-nomination table with immunogenicity, impurity/characterization, increased heart rate, and systemic vasodilatory-reaction language. Ipamorelin acetate remains Category 2 under the 503B interim policy and is also listed among withdrawn nominations, with IV gastric-motility serious-adverse-event language including death. FDA does not establish causality in that sentence, and route matters.
Regulatory source
List of Bulk Drug Substances That Can Be Used To Compound Drug Products in Accordance With Section 503A of the Federal Food, Drug, and Cosmetic Act84 FR 4696. 2019
Regulatory source — United States
The 2019 final 503A bulks rule placed six substances on the list and identified four that were not included. CJC-1295 and Ipamorelin are not among those listed substances.
Anti-doping source
The 2026 Prohibited ListWADA Prohibited List 2026. 2026
Anti-doping source — WADA
Anti-doping status is not a medical or regulatory approval decision. Athletes should verify the current official list.
Anti-doping source
The 2026 Prohibited List (official PDF)WADA Prohibited List 2026. 2026
Anti-doping source — WADA
Section S2.2.4 names CJC-1295 as a GHRH analogue and ipamorelin as a growth hormone secretagogue / mimetic. Anti-doping status is informational and is not a medical approval decision. Detection windows and evasion information are not used.
Peptra Health materials are for laboratory research use only. This article is educational and is not medical advice.